⁶⁸Ga-PD-L1

⁶⁸Ga-PD-L1 (Gallium-68 labeled Programmed Death-Ligand 1) refers to a class of radiolabeled positron emission tomography (PET) imaging tracers designed to non-invasively assess PD-L1 expression in vivo. These tracers typically consist of a PD-L1-targeting moiety—such as a monoclonal antibody, single-domain antibody (nanobody), or small peptide (e.g., WL12)—conjugated to a chelator (e.g., DOTA, NOTA, HBED-CC) and labeled with the positron-emitting radioisotope Gallium-68 (⁶⁸Ga). By binding specifically to PD-L1 overexpressed on tumor cells and immune cells within the tumor microenvironment, ⁶⁸Ga-PD-L1 PET/CT imaging allows for the real-time, whole-body evaluation of PD-L1 status. This imaging approach serves as a complementary functional biomarker to guide patient selection and monitor responses to immune checkpoint inhibitor therapies targeting the PD-1/PD-L1 pathway, particularly in solid malignancies such as non-small cell lung cancer (NSCLC).

Other names

68Ga-PD-L1[68Ga]Ga-PD-L1Gallium-68 PD-L1Gallium68 PD-L1Gallium 68 PD-L1⁶⁸Ga-labeled PD-L1